Mitchell & Pahl Private Wealth’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.4M Buy
7,369
+227
+3% +$42.7K 0.51% 66
2026
Q1
$1.41M Sell
7,142
-2
-0% -$386 0.57% 67
2025
Q4
$1.31M Sell
7,144
-42
-0.6% -$7.37K 0.55% 69
2025
Q3
$1.1M Buy
7,186
+3
+0% +$454 0.46% 78
2025
Q2
$1M Buy
7,183
+357
+5% +$50K 0.44% 80
2025
Q1
$1M Sell
6,826
-110
-2% -$15.9K 0.47% 75
2024
Q4
$909K Buy
6,936
+385
+6% +$53.9K 0.42% 84
2024
Q3
$1.02M Sell
6,551
-25
-0.4% -$4.04K 0.48% 79
2024
Q2
$1.03M Sell
6,576
-55
-0.8% -$8.28K 0.54% 73
2024
Q1
$899K Buy
6,631
+358
+6% +$47.4K 0.47% 78
2023
Q4
$845K Sell
6,273
-112
-2% -$14.6K 0.48% 79
2023
Q3
$865K Buy
6,385
+614
+11% +$83.9K 0.51% 67
2023
Q2
$826K Buy
5,771
+92
+2% +$13.5K 0.5% 69
2023
Q1
$788K Buy
5,679
+95
+2% +$12.8K 0.49% 73
2022
Q4
$757K Buy
5,584
+682
+14% +$85.5K 0.5% 77
2022
Q3
$538K Buy
4,902
+231
+5% +$29.3K 0.4% 90
2022
Q2
$617K Buy
4,671
+122
+3% +$16K 0.43% 87
2022
Q1
$604K Buy
4,549
+591
+15% +$70.9K 0.38% 87
2021
Q4
$461K Buy
3,958
+298
+8% +$35.1K 0.3% 104
2021
Q3
$440K Buy
3,660
+100
+3% +$11.6K 0.32% 96
2021
Q2
$426K Buy
3,560
+180
+5% +$19.7K 0.3% 103
2021
Q1
$336K Buy
3,380
+258
+8% +$25.9K 0.26% 114
2020
Q4
$312K Buy
+3,122
New +$331K 0.26% 113

Other funds holding AZN

Mitchell & Pahl Private Wealth's AZN Position: Q2 2026 in Review

Mitchell & Pahl Private Wealth increased its AstraZeneca (AZN) stake by 3.2% in Q2 2026, buying an estimated $42.7K and bringing the position to 7,369 shares worth $1.4M. The position accounts for 0.51% of the portfolio, ranked #66.

Mitchell & Pahl Private Wealth first reported a position in AZN in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.41M in Q1 2026. 269 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Mitchell & Pahl Private Wealth held 7,369 shares of AstraZeneca worth $1.4M as of Q2 2026.
  • Mitchell & Pahl Private Wealth bought 227 AstraZeneca shares in Q2 2026, an estimated $42.7K.
  • AstraZeneca made up 0.51% of Mitchell & Pahl Private Wealth's portfolio in Q2 2026, its #66 holding.
  • Mitchell & Pahl Private Wealth first reported a position in AstraZeneca in Q4 2020 and has held it in 23 quarters since.
  • Mitchell & Pahl Private Wealth's AstraZeneca position peaked at $1.41M in Q1 2026.
  • 269 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Mitchell & Pahl Private Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.